Loading…
Fischer Medical Ventures (FISCHER)₹24.94+0.28%Medical Equipment & Supplies
In the Jun 2026 quarter (consolidated), Fischer Medical Ventures reported sales of ₹81.89 Cr, up 249.5% from Jun 2025, and net profit of ₹3.81 Cr, down 21.9% year on year. For the year to Mar 2026, sales were ₹309 Cr and net profit ₹31.11 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20.78 | 10.11 | 39.63 | 11.74 | 49.18 | 23.43 | 86.25 | 101 | 97.47 | 81.89 |
| Expenses | 18.30 | 10.35 | 39.19 | 11.39 | 46.68 | 19.48 | 70.18 | 79.66 | 101 | 70.70 |
| Operating Profit | 2.50 | −0.22 | 0.49 | 0.38 | 2.52 | 3.98 | 16.21 | 21.55 | −3.76 | 11.24 |
| OPM % | 12.0% | −2.1% | 1.3% | 3.1% | 5.1% | 17.0% | 18.8% | 21.3% | −3.9% | 13.7% |
| Other Income | 0.46 | 0.68 | 0.04 | 0.37 | 0.14 | 7.46 | 2.47 | 1.08 | 0.76 | 1.47 |
| Interest | 0.06 | 0.14 | 0.06 | 0.08 | 0.24 | 0.67 | 0.93 | 0.65 | 3.67 | 3.55 |
| Depreciation | 0.19 | 0.27 | 0.30 | 0.55 | 0.50 | 0.78 | 0.52 | 0.78 | 0.94 | 1.37 |
| Profit before tax | 2.74 | 0.06 | 0.20 | 0.11 | 1.91 | 10.01 | 17.24 | 21.22 | −7.58 | 7.82 |
| Tax % | 6.2% | 271.5% | −38.0% | 350.1% | 26.1% | 51.6% | 19.5% | 9.2% | 64.1% | 51.6% |
| Exceptional items | 0.00 | 0.09 | −0.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 2.60 | −0.13 | 0.30 | −0.30 | 1.32 | 4.88 | 13.96 | 19.29 | −12.49 | 3.81 |
| EPS (Rs) | 0.06 | 0.00 | 0.02 | −0.02 | 0.03 | 0.08 | 0.22 | 0.31 | −0.20 | 0.07 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales | 0.00 | 20.99 | 111 | 309 | 367 |
| Expenses | 0.00 | 19.03 | 108 | 266 | 322 |
| Operating Profit | 0.00 | 1.99 | 3.01 | 42.97 | 45.24 |
| OPM % | 11.0% | 9.0% | 2.6% | 14.0% | 12.3% |
| Other Income | 0.00 | 0.00 | 0.99 | 11.98 | 5.78 |
| Interest | 0.00 | 0.00 | 0.00 | 6.01 | 8.80 |
| Depreciation | 0.00 | 0.00 | 1.99 | 3.01 | 3.61 |
| Profit before tax | 0.00 | 1.99 | 1.99 | 45.93 | 38.70 |
| Tax % | — | 13.0% | 45.1% | 33.1% | — |
| Net Profit | 0.00 | 2.01 | 1.01 | 31.11 | 24.57 |
| EPS (Rs) | −0.25 | 0.04 | 0.03 | 0.48 | 0.40 |
| Dividend payout % | 0.0% | 0.0% | 22.0% | 11.0% | — |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.17 | 54.13 | 64.24 | 65.20 |
| Reserves | 0.00 | 27.96 | 274 | 318 |
| Borrowings | 1.00 | 2.01 | 85.26 | 107 |
| Other Liabilities | 0.00 | 4.02 | 34.16 | 181 |
| Total Liabilities | 0.00 | 86.12 | 457 | 673 |
| Fixed Assets | 0.00 | 14.97 | 23.96 | 32.96 |
| CWIP | 0.00 | 0.00 | 1.01 | 3.01 |
| Investments | 0.00 | 1.01 | 11.02 | 123 |
| Other Assets | 0.00 | 70.14 | 421 | 514 |
| Inventories | 0.00 | 3.99 | 8.98 | 12.98 |
| Trade receivables | 0.00 | 22.93 | 75.78 | 288 |
| Cash & equivalents | 0.00 | 38.10 | 252 | 25.08 |
| Total Assets | 0.00 | 86.12 | 457 | 673 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | −6.99 | −86.73 | −101 |
| Cash from investing activity | −28.92 | −125 | −4.99 |
| Cash from financing activity | 36.97 | 315 | 13.99 |
| Net cash flow | 0.99 | 103 | −91.66 |
| Capex | 0.00 | 5.98 | 0.99 |
| Free cash flow | −8.01 | −93.09 | −103 |
| CFO / OP % | −392.0% | −3,001.0% | −195.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 345 | 398 | 251 | 342 |
| Inventory days | — | 99 | 36 | 24 |
| Days payable | — | 49 | 83 | 192 |
| Cash conversion cycle | 345 | 449 | 205 | 174 |
| Working capital days | 325 | 499 | 41 | 156 |
| ROCE % | — | 5.0% | 1.0% | 11.0% |
For the Jun 2026 quarter, Fischer Medical Ventures reported sales of ₹81.89 Cr, up 249.5% year on year and net profit of ₹3.81 Cr, down 21.9% year on year. The operating margin was 13.7%.
Fischer Medical Ventures' sales for the year to Mar 2026 were ₹309 Cr; over the last twelve months they were ₹367 Cr.
Net profit for the year to Mar 2026 was ₹31.11 Cr, and ₹24.57 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.40.
Fischer Medical Ventures reported borrowings of ₹107 Cr at Mar 2026, against cash and equivalents of ₹25.08 Cr.
Cash from operations was −₹101 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹103 Cr.